Drug Trial Radar · NCT06617000
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
38
Planned (sponsor's estimate)
Start
Oct 25, 2022
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- SCG Cell Therapy Pte. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Conditions
- HCC
- Hepatitis B Virus Related Hepatocellular Carcinoma
- Hepatocellular Carcinoma
Interventions
SCG101Biological
Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT) and adverse events (AEs), including serious AEs (SAEs), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).Time frame: Start of SCG101 infusion until disease progression or 12 months post infusion
- The preliminary clinical efficacy of SCG101, including objective response rate (ORR), disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), and overall survival (OS).Time frame: Start of SCG101 infusion until disease progression or 12 months post infusion
- Change in pharmacodynamics markers (PD) before and after SCG101 infusionTime frame: Start of SCG101 infusion until disease progression, an average of 24 months
- Persistences of viral vector copy number (VCN) after SCG101 infusionTime frame: Start of SCG101 infusion until disease progression, an average of 24 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing
Beijing, Beijing Municipality, China · Recruiting
Guangzhou
Guangzhou, Guangdong, China · Recruiting
Zhengzhou
Zhengzhou, Henan, China · Recruiting
Changchun
Changchun, Jilin, China · Recruiting
Shenyang
Shenyang, Liaoning, China · Recruiting
Ji'nan
Ji'nan, Shandong, China · Recruiting
Shanghai
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.